Publications by authors named "Mauro Valeriano D'Auria"
Article Synopsis
- Bowel ultrasonography (BUS) is a noninvasive method used to assess bowel activity in patients with Crohn's disease (CD), and this study aimed to evaluate its effectiveness in tracking improvements after various biological therapies.
- In a multicenter study involving 188 adult CD patients across 16 sites in Italy, BUS parameters like bowel wall thickening and transmural healing were analyzed at different time points after treatment, showing significant improvement after 3 and 12 months.
- The results highlighted that BUS can effectively monitor changes in bowel activity related to biological therapies, indicating its potential as a valuable tool in managing CD.
Background: Mesalazine 1 g suppository/die is used for mild to moderately active ulcerative proctitis (UP). Whether addiction of Multi Matrix System (MMX) mesalazine increases the remission rate of UP and prevents proximal extension of disease is unknown.
Methods: This is a retrospective study on 116 outpatients with UP who had been treated with one of the following regimens: (1) MMX mesalazine 1.
Oxidative stress leads to chronic liver damage. Silybin has been conjugated with vitamin E and phospholipids to improve its antioxidant activity. Eighty-five patients were divided into 2 groups: those affected by nonalcoholic fatty liver disease (group A) and those with HCV-related chronic hepatitis associated with nonalcoholic fatty liver disease (group B), nonresponders to treatment.
View Article and Find Full Text PDFObjectives: To evaluate whether chronic therapy with probiotics affects plasma levels of cytokines and oxidative/nitrosative stress parameters, as well as liver damage, in patients with various types of chronic liver disease.
Patients And Methods: A total of 22 nonalcoholic fatty liver disease (NAFLD) and 20 alcoholic liver cirrhosis (AC) patients were enrolled in the study and compared with 36 HCV-positive patients with chronic hepatitis without (20, CH) or with (16, CC) liver cirrhosis. All patients were treated with the probiotic VSL#3.